DeepMed Research

Aliskiren

Generic Name: Aliskiren

Brand Names: Rasilez, Tekturna, Tekturna Hct

Drug Type: Small Molecule

Chemical Formula: C_₃₀H_₅₃N_₃O_₆

CAS Number: 173334-57-1

Unique Ingredient Identifier: 502FWN4Q32

Background: Aliskiren is the first drug in the renin inhibitor drug class and is used for the treatment of hypertension. It was developed by Speedel and Novartis and initially approved by the FDA in early 2007. Aliskiren has been proven to efficacious in reducing blood pressure when used alone or in conjunction with other antihypertensive agents.

Indication: Aliskiren is used for the treatment of hypertension in children above 6 years and adults. This drug may also be used in conjunction with antihypertensives such as calcium channel blockers and thiazides in products form to provide additional blood pressure control.

Associated Conditions: Hypertension

Clinical Trials

Add-on Aliskiren Treatment in Patients With Chronic Congestive Heart Failure

Phase 4

Conditions: Congestive Heart Failure

Interventions: Drug: Aliskiren
Drug: Placebo

First Posted Date: 2009-12-29

Last Posted Date: 2010-01-20

Lead Sponsor: National Taiwan University Hospital

Target Recruit Count: 60

Registration Number: NCT01040494

Locations: 🇨🇳
Taipei Veteral General Hospital, Taipei, Taiwan
🇨🇳
National Taiwan University Hospital, Taipei, Taiwan

Evaluating the Effect of Aliskiren Versus HCTZ on Coronary Flow Reserve in Hypertensive Type II Diabetics

Phase 4

Withdrawn

Conditions: Hypertension
Diabetes Type 2

Interventions: Drug: Aliskiren
Drug: Hydrochlorothiazide

First Posted Date: 2009-10-14

Last Posted Date: 2017-10-02

Lead Sponsor: William Beaumont Hospitals

Registration Number: NCT00994253

Locations: 🇺🇸
William Beaumont Hospital, Royal Oak, Michigan, United States

Effects of Aliskiren on Patient With Heart Failure and a Normal Ejection Fraction

Phase 4

Completed

Conditions: Heart Failure

Interventions: Drug: placebo
Drug: aliskiren

First Posted Date: 2009-09-22

Last Posted Date: 2019-02-27

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 52

Registration Number: NCT00982033

Locations: 🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States

Vitamin D Deficiency in Patients With Hypertension

Phase 4

Terminated

Conditions: Vitamin D Deficiency
Hypertension

Interventions: Drug: Aliskiren
Dietary Supplement: Cholecalciferol
Dietary Supplement: Placebo

First Posted Date: 2009-09-11

Last Posted Date: 2018-03-09

Lead Sponsor: UConn Health

Target Recruit Count: 40

Registration Number: NCT00974922

Locations: 🇺🇸
University of Connecticut Health Center, Farmington, Connecticut, United States

Triple Blockade of the Renin Angiotensin Aldosterone System in Diabetic (Type 1&2) Proteinuric Patients

Phase 4

Terminated

Conditions: Microalbuminuria
Macroalbuminuric Diabetic Nephropathy
Diabetes
Proteinuria
Albuminuria

Interventions: Drug: Aliskiren

First Posted Date: 2009-08-18

Last Posted Date: 2013-10-28

Lead Sponsor: Cook County Health

Target Recruit Count: 2

Registration Number: NCT00961207

Locations: 🇺🇸
John H Stroger Hospital of Cook County, Chicago, Illinois, United States

Safety of Add on Aliskiren to Angiotensin Converting Enzyme Inhibitor (ACEI) and Angiotensin I Receptor Blocker (ARB) Treatment in Type 2 Diabetes With Nephropathy

Phase 4

Conditions: Type 2 Diabetes With Nephropathy

Interventions: Drug: Aliskiren 300mg/d

First Posted Date: 2009-07-30

Last Posted Date: 2009-07-30

Lead Sponsor: Lerdsin General Hospital

Target Recruit Count: 80

Registration Number: NCT00949351

Locations: 🇹🇭
Lerdsin General Hospital, Bangkok, Thailand

The Effect of Renin Inhibition on Nerve Function in Diabetes

Not Applicable

Completed

Conditions: Diabetes

Interventions: Drug: Aliskiren
Other: Placebo

First Posted Date: 2009-07-08

Last Posted Date: 2016-08-09

Lead Sponsor: Christiana Care Health Services

Target Recruit Count: 60

Registration Number: NCT00935064

Locations: 🇺🇸
Christiana Care Health Services, Newark, Delaware, United States

Effect of Light Meal on Pharmacokinetic and Pharmacodynamics of Aliskiren in Patients With Mild to Moderate Hypertension

Phase 1

Completed

Conditions: Hypertension

Interventions: Drug: Aliskiren

First Posted Date: 2009-07-07

Last Posted Date: 2020-12-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 124

Registration Number: NCT00933920

Locations: 🇮🇳
Novartis Investigative Site, New Delhi, India
🇮🇳
Novartis Investigator Site, Mangalore, India

Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus

Phase 4

Completed

Conditions: Hypertension

Interventions: Drug: Aliskiren
Drug: Valsartan
Drug: Placebo for Aliskiren
Drug: Placebo for Valsartan

First Posted Date: 2009-06-25

Last Posted Date: 2012-12-06

Lead Sponsor: Novartis

Target Recruit Count: 1143

Registration Number: NCT00927394

Locations: 🇺🇸
Investigative Site, Philadelphia, Pennsylvania, United States

Effects of Aliskiren, Ramipril, and the Combination on Levels of Angiotensin II in Patients With Decompensated Systolic Heart Failure

Phase 2

Completed

Conditions: Heart Failure

Interventions: Drug: aliskiren
Drug: ramipril
Drug: Placebo to aliskiren
Drug: Placebo to ramipril

First Posted Date: 2009-06-18

Last Posted Date: 2012-07-26

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 123

Registration Number: NCT00923156

Locations: 🇷🇺
Novartis Investigative Site, Moscow, Russian Federation
🇷🇺
Novartis Investigator Site, Moscow, Russian Federation

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy